NeuroOne CTO granted options on 15,000 shares

NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) reported that Chief Technology Officer Steve Mertens received a grant of an option to purchase 15,000 shares of common stock.

Rhea-AI Filing Summary

NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) reported that Chief Technology Officer Steve Mertens received a grant of an option to purchase 15,000 shares of common stock. The option has an exercise price of $1.77 per share and expires on August 27, 2036. According to the vesting terms, 25% of the option will vest on August 28, 2027, with the remaining 75% vesting in 12 equal quarterly installments thereafter. Following this grant, Mertens holds 15,000 derivative securities directly.

Insider Trade Summary

Grant/Award: 15,000 shares

Grant/Award 1 txn

Insider Mertens Steve

Role Chief Technology Officer

Type	Security	Shares	Price	Value
Grant/Award	Option to Purchase Common Stock F1	15,000	$0.00	$0.00

Holdings After Transaction: Option to Purchase Common Stock — 15,000 contracts (Direct)

Footnotes (1)

1. F1. 25% will vest on August 28, 2027, and the remaining 75% will vest in 12 equal quarterly installments.

Key Figures

Option grant size: 15,000 options Exercise price: $1.77 per share Expiration date: August 27, 2036 +3 more

6 metrics

Option grant size 15,000 options Options to purchase common stock granted to CTO Steve Mertens

Exercise price $1.77 per share Conversion or exercise price of the stock options

Expiration date August 27, 2036 Option to purchase common stock expiration

Post-transaction derivative holdings 15,000 options Total derivative securities held directly after the grant

Initial vesting portion 25% Vests on August 28, 2027

Remaining vesting portion 75% Vests in 12 equal quarterly installments after August 28, 2027

Key Terms

Option to Purchase Common Stock, exercise price, vesting, quarterly installments

4 terms

Option to Purchase Common Stock financial

"security_title: Option to Purchase Common Stock"

exercise price financial

"conversion_or_exercise_price: 1.7700"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"25% will vest on August 28, 2027, and the remaining 75%"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

quarterly installments financial

"remaining 75% will vest in 12 equal quarterly installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did NMTC’s Chief Technology Officer receive in this Form 4 filing?

The Chief Technology Officer, Steve Mertens, received a grant of an option to purchase 15,000 shares of NEUROONE MEDICAL TECHNOLOGIES Corp common stock at an exercise price of $1.77 per share, expiring on August 27, 2036.

How do the new NMTC stock options for Steve Mertens vest?

The option vests 25% on August 28, 2027. The remaining 75% will vest in 12 equal quarterly installments after that date, as disclosed in the footnote to the Form 4.

What is the exercise price of the NMTC options granted to Steve Mertens?

The options granted to Chief Technology Officer Steve Mertens have an exercise price of $1.77 per share for NEUROONE MEDICAL TECHNOLOGIES Corp common stock.

When do the NMTC options granted to Steve Mertens expire?

The options to purchase NEUROONE MEDICAL TECHNOLOGIES Corp common stock granted to Steve Mertens expire on August 27, 2036, if not exercised or forfeited earlier under their terms.

How many NMTC derivative securities does Steve Mertens hold after this transaction?

After the reported grant, Steve Mertens holds 15,000 derivative securities (options) relating to NEUROONE MEDICAL TECHNOLOGIES Corp common stock, all held with direct ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/28/2026 - 04:58 PM EDT Accepted by SEC EDGAR 08/28/2026 - 04:57 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mertens Steve

(Last) (First) (Middle)

7599 ANAGRAM DR.

(Street)

EDEN PRAIRIE MINNESOTA 55344

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEUROONE MEDICAL TECHNOLOGIES Corp [ NMTC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	$1.77	08/28/2026		A		15,000		(1)	08/27/2036	Common Stock	15,000	$0	15,000	D

Explanation of Responses:

1. 25% will vest on August 28, 2027, and the remaining 75% will vest in 12 equal quarterly installments.

	/s/ Emily Johns, by Power of Attorney	08/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)